Welcome to our dedicated page for WORK Medical Technology Group SEC filings (Ticker: WOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The WORK Medical Technology Group LTD (WOK) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer in the medical devices sector. WORK Medical files annual reports on Form 20-F and current reports on Form 6-K, detailing its operations in developing and manufacturing Class I and II medical devices and selling Class I and II disposable medical devices through subsidiaries in China.
In these filings, investors can review information on WORK Medical’s product portfolio of medical consumables and equipment, its sales footprint across 34 provincial-level administrative regions in China, and the registration of 17 products with the U.S. Food and Drug Administration. Form 6-K reports provide updates on interim financial statements and management’s discussion and analysis, extraordinary general meetings and voting results, changes in independent auditors, and capital markets transactions such as registered direct offerings, at-the-market sales agreements, and pre-funded warrants.
Filings also describe share structure changes and Nasdaq listing matters, including approved share consolidations (reverse stock splits), increases in authorized share capital, and correspondence with Nasdaq regarding minimum bid price compliance and potential delisting determinations. These documents outline the reasons for share consolidations, effective dates, and post-consolidation share counts, giving context to changes in the company’s capital structure.
On Stock Titan, users can access WORK Medical’s Forms 6-K and 20-F as they are furnished to the SEC’s EDGAR system, along with AI-powered summaries that highlight key points such as financing terms, governance changes, and listing status updates. The filings page is also a reference point for tracking any future registration statements, prospectus supplements, and other transactional documents that the company incorporates by reference into its shelf registration statements.
WORK Medical Technology Group (WOK) consolidated its shares 100:1, effective October 21, 2025, to address Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and mitigate delisting risk. The company has until April 6, 2026 to regain compliance.
As of October 20, 2025, the company had 103,591,276 ordinary shares outstanding (95,998,776 Class A; 7,592,500 Class B). After the consolidation, there were approximately 1,035,913 ordinary shares outstanding (about 959,988 Class A; 75,925 Class B), subject to rounding up of fractional shares to whole shares.
The ticker remains “WOK,” and the Class A shares now trade under CUSIP G9767H117. Authorized capital increased to US$10,000,000, divided into 160,000,000 Class A ordinary shares of par value US$0.05 each and 40,000,000 Class B ordinary shares of par value US$0.05 each. Shareholders holding electronically did not need to take action.
L1 Capital Global Opportunities Master Fund, Ltd. filed a Schedule 13G reporting beneficial ownership of 7,897,548 Class A Ordinary Shares of WORK Medical Technology Group LTD, representing 9.99% of the class. The fund has sole voting and sole dispositive power over the same number of shares.
The filing notes this percentage is based on 79,054,538 Class A Ordinary Shares outstanding after the offering, as referenced in a Prospectus Supplement filed on September 26, 2025 and a Form 6-K filed on September 29, 2025. It excludes 5,102,230 pre-funded warrants due to a 9.99% beneficial ownership limitation. The certification states the securities were not acquired to change or influence control. The event date triggering the filing was September 26, 2025, and the statement was signed by Director David Feldman on October 3, 2025.
WORK Medical Technology Group LTD (WOK) Schedule 13G discloses that Bigger Capital Fund, LP and related reporting persons beneficially owned 7,897,548 Class A Ordinary Shares as of September 25, 2025, representing approximately 9.99% of the Class A shares outstanding immediately after the offering (79,054,538 shares basis). The filing states the holdings exclude 5,102,230 Class A Ordinary Shares issuable upon exercise of pre-funded warrants subject to a 9.99% ownership limitation. Reporting persons disclaim sole ownership and state the stake is not held to influence control.
WORK Medical Technology Group LTD reported that it completed a registered direct offering with institutional investors. The company issued 22,055,096 Class A ordinary shares and pre-funded warrants to purchase up to 16,944,238 Class A ordinary shares, each priced at $0.075. This generated approximately $2.9 million in gross proceeds, which the company plans to use for working capital and general corporate purposes.
Each pre-funded warrant has an exercise price of $0.0005 per share and was immediately exercisable, and all of these warrants were fully exercised on September 25, 2025. Company directors, executive officers, and 10% and larger shareholders agreed to a 90-day lock-up on sales of their securities. WORK Medical also agreed not to enter into variable-rate equity transactions for 45 days and not to issue additional shares or file new registration statements for 30 days, subject to specified exceptions. Univest Securities, LLC acted as exclusive placement agent, earning a cash fee of 8.0% of gross proceeds plus up to $100,000 of reimbursed expenses.
WORK Medical Technology Group LTD is offering Class A Ordinary Shares at $0.075 per share, with 56,999,442 Class A Ordinary Shares to be issued (and 95,998,776 shares assuming full exercise of Pre-Funded Warrants). The prospectus supplement states net proceeds will be used for working capital and general corporate purposes. The document highlights extensive risk factors tied to its PRC operations, including potential PRC government intervention, uncertainties in interpretation and enforcement of PRC laws, cybersecurity review rules, restrictions on using offshore proceeds to fund PRC subsidiaries, and the risk of delisting under the HFCA Act if PCAOB inspection is prevented. The company notes its dual-class share structure, potential dilution from future issuances and Pre-Funded Warrant exercise, and that it does not expect to pay dividends in the foreseeable future.
WORK Medical Technology Group LTD, a Cayman Islands company and foreign private issuer, filed a Form 6-K to furnish its unaudited consolidated financial statements and notes for the six months ended March 31, 2025. These financial statements are provided as Exhibit 99.1.
The company also furnished Management’s Discussion and Analysis of Financial Condition and Results of Operations for the same six-month period as Exhibit 99.2. Additional Inline XBRL data files and the cover page interactive data file are included among the technical exhibits.
WORK Medical Technology Group LTD filed a Form 6-K as a foreign private issuer to distribute materials for an upcoming extraordinary general meeting of shareholders. The company is furnishing the official notice and proxy statement for the meeting, along with a proxy card that shareholders can use to vote. These documents are provided as Exhibits 99.1 and 99.2 and will be mailed to shareholders. The filing is mainly procedural, ensuring investors receive the necessary information and voting forms for the meeting.